• Treatment of vaginal oestrogen deficiency symptoms: • Treatment of symptoms of vaginal atrophy due to oestrogen deficiency in postmenopausal women. • As pre-surgery therapy for vaginal operations and during subsequent convalescence.
Allergan announced the approval of Rhofade cream (oxymetazoline HCI cream 1.0%) by the U.S. FDA for the topical treatment of...
Galderma Laboratories, L.P. has announced on 24 December 2014 the FDA approved Soolantra (ivermectin) Cream, 1% for the once-daily topical...
Galderma announced that the FDA approved Aklief (trifarotene) Cream, 0.005% for the topical treatment of acne. Trifarotene is the first...
Dipexium Pharmaceuticals, Inc. announced that the OneStep-1 and OneStep-2 Phase III clinical trials of Locilex (pexiganan cream 0.8%) in patients...
LEO Pharma announced positive results of the DELTA 2 trial. DELTA 2 is the second of two pivotal phase III clinical trials with delgocitinib cream, an investigational topical pan-Janus kinase (JAK)-inhibitor, for the potential treatment of adults with moderate to severe chronic hand eczema (CHE).
Leo Pharma A/S announces that the European Medicines Agency (EMA) has validated the marketing authorization application (MAA) for delgocitinib cream, an investigational product and topical pan-Janus kinase (JAK) inhibitor for the treatment of adult patients with moderate to severe chronic hand eczema (CHE)
Sol-Gel Technologies, Ltd. announced the FDA approval of its drug product, Epsolay, a proprietary cream formulation of benzoyl peroxide, 5%, for the treatment of inflammatory lesions of rosacea in adults.
Arcutis Biotherapeutics, Inc. announced positive topline results from the DERMIS-1 and DERMIS-2 pivotal Phase III studies evaluating roflumilast cream (ARQ 151) as a potential topical treatment for plaque psoriasis.